Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-8201a in Chinese patients with HER2+ gastric or breast cancer
NCT03368196Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2018
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trastuzumab deruxtecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and breast cancer, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Treatment-emergent Adverse Events. Started Apr 2018; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomabreast cancer
Beyond the preview
Go deeper on NCT03368196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03368196.